Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Vaccines

Free Subscription 21.04.2025 2 Clin Infect Dis 1 J Immunol 5 J Infect Dis 7 J Virol 1 Lancet 1 Pediatr Infect Dis J 2 PLoS Biol 1 PLoS Comput Biol 4 PLoS One 18 Vaccine 1 Virology 2 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Clin Infect Dis

1. TORCEL-PAGNON L, Coudeville L, Harris RC, Chaves SS, et al
   The Impact of Influenza on US Working-Age Adults: Exploring the Benefits of the Recombinant Influenza Vaccine.
   Clin Infect Dis. 2025 Apr 17:ciaf200. doi: 10.1093.
   PubMed         Abstract available
   
   
2. MESSCHENDORP AL, Zaeck LM, Bouwmans P, van den Broek DAJ, et al
   Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial.
   Clin Infect Dis. 2025 Apr 15:ciaf107. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Immunol

3. DING C, Chen Q, Shi Y, Liu J, et al
   Impact of CD4+ T cell and TCR repertoires on SARS-CoV-2-Specific antibody responses in PLWH following COVID-19 vaccination.
   J Immunol. 2025 Apr 15:vkae040. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect Dis

4. CHEN H, Huang X, Wang C, Cowling BJ, et al
   Estimating the waning effectiveness of COVID-19 vaccines from population-level surveillance data in Hong Kong.
   J Infect Dis. 2025 Apr 18:jiaf207. doi: 10.1093.
   PubMed         Abstract available
   
   
5. CORTIER T, Gilboa M, Layan M, Joseph G, et al
   Factors Associated With the Transmission of the Delta Severe Acute Respiratory Syndrome Coronavirus 2 Variant in Households: The Israeli COVID-19 Family Study (ICoFS).
   J Infect Dis. 2025;231:e734-e742.
   PubMed         Abstract available
   
   
6. GRAY P, Wang J, Nordqvist Kleppe S, Elfstrom KM, et al
   Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence.
   J Infect Dis. 2025;231:e638-e649.
   PubMed         Abstract available
   
   
7. WILSON GJ, Church LWP, Kelley CF, Robinson ST, et al
   HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
   J Infect Dis. 2024 Dec 13:jiae558. doi: 10.1093.
   PubMed         Abstract available
   
   
8. CHO HK, Frivold C, Chu HY
   Maternal Immunization.
   J Infect Dis. 2025;231:830-836.
   PubMed         Abstract available
   
   

   
   J Virol

9. KEEP S, Foldes K, Dowgier G, Freimanis G, et al
   Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.
   J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663.
   PubMed         Abstract available
   
   
10. LOU Y-N, Sun M-X, Li K, Xiong X-C, et al
    A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.
    J Virol. 2025;99:e0177024.
    PubMed         Abstract available
    
    
11. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed         Abstract available
    
    
12. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed         Abstract available
    
    
13. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    PubMed         Abstract available
    
    
14. THIONO DJ, Samaras D, Phan TTN, Zhu DR, et al
    Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.
    J Virol. 2025 Apr 16:e0022925. doi: 10.1128/jvi.00229.
    PubMed         Abstract available
    
    
15. LI Y, Yang S, Qian J, Liu S, et al
    Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
    J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
    PubMed         Abstract available
    
    

    
    Lancet

16. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
    Accelerating vaccine development in Africa: lessons from HIV research.
    Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
    PubMed        
    
    

    
    Pediatr Infect Dis J

17. BUTIC I, Tesovic G, Bodulic K, Lucic S, et al
    Impact of Universal PCV10 Vaccination on Invasive Pneumococcal Disease in Croatian Children.
    Pediatr Infect Dis J. 2025 Apr 8. doi: 10.1097/INF.0000000000004821.
    PubMed         Abstract available
    
    

    
    PLoS Biol

18. MARZI A
    One-for-one or one-for-all? Considerations for filovirus vaccine development.
    PLoS Biol. 2025;23:e3003142.
    PubMed         Abstract available
    
    
19. PARIENTE N
    Vaccines work... and do not cause autism.
    PLoS Biol. 2025;23:e3003143.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

20. SBARRA AN, Haeuser E, Kidane S, Abate A, et al
    Fitting dynamic measles models to subnational case notification data from Ethiopia: Methodological challenges and key considerations.
    PLoS Comput Biol. 2025;21:e1012922.
    PubMed         Abstract available
    
    

    
    PLoS One

21. IWU CD, Shrestha P, Littman AJ, Hood JE, et al
    The association between healthcare access and shingles vaccination among older adults in Virginia, United States.
    PLoS One. 2025;20:e0316429.
    PubMed         Abstract available
    
    
22. VILLOTA SD, Veloz-Villavicencio E, Garcia-Iturralde S, Arevalo JV, et al
    Validation of new equipment for SARS-CoV-2 diagnosis in Ecuador: Detection of the virus and antibodies generated by disease and vaccines with one POC device.
    PLoS One. 2025;20:e0321794.
    PubMed         Abstract available
    
    
23. OROTTA M, Munseri P, Massawe RV, Orotta GM, et al
    Hepatitis B virus: Prevalence, vaccination coverage and immune responses to immunization among healthcare workers at Muhimbili National Hospital.
    PLoS One. 2025;20:e0321623.
    PubMed         Abstract available
    
    
24. XIE M, Younas Khan M, Ullah S, Farooq M, et al
    Optimal control analysis for the transmission of Nipah infection with imperfect vaccination.
    PLoS One. 2025;20:e0317408.
    PubMed         Abstract available
    
    

    
    Vaccine

25. DE MELO ARAUJO AC, Oliveira TM, Souza JFA, da Fonseca Victer TN, et al
    Incorporating vaccines into vaccination schedules around the world: A scoping review.
    Vaccine. 2025;54:127132.
    PubMed         Abstract available
    
    
26. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    PubMed         Abstract available
    
    
27. ARSENAULT C, Ravishankar S, Lewis T, Armeni P, et al
    The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States.
    Vaccine. 2025;54:127134.
    PubMed         Abstract available
    
    
28. STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
    Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
    Vaccine. 2025;54:127136.
    PubMed         Abstract available
    
    
29. WANG Z, Wang M, Wang F, Luo Y, et al
    Corrigendum to "Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models" [Vaccine 42
    Vaccine. 2025;54:127126.
    PubMed        
    
    
30. URIU K, Kaku Y, Kihara M, Sato K, et al
    Antiviral humoral immunity against SARS-CoV-2 omicron JN.1 subvariants induced by JN.1 recombinant protein vaccine.
    Vaccine. 2025;54:127129.
    PubMed        
    
    
31. TONG F, Zhou T, Tang L, Wu X, et al
    Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
    Vaccine. 2025;54:127004.
    PubMed         Abstract available
    
    
32. ZHANG L, Xia Y, Chu L, Sundaram ME, et al
    Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
    Vaccine. 2025;53:127106.
    PubMed         Abstract available
    
    
33. DYMOCK M, Marsh JA, Murray K, Snelling TL, et al
    What is the quality of evidence informing vaccine clinical practice recommendations in Australia?
    Vaccine. 2025;53:127105.
    PubMed         Abstract available
    
    
34. BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
    Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
    Vaccine. 2025;53:127074.
    PubMed         Abstract available
    
    
35. JOHN TJ, Dharmapalan D, Steinglass R, Hirschhorn N, et al
    Lessons for polio eradication from the geographic variations of vaccine efficacy of oral polio.
    Vaccine. 2025;53:127115.
    PubMed        
    
    
36. JOSHI R, Ayele HT, Johnson KD, Velentgas P, et al
    Anticipated impact of novel adult-specific pneumococcal conjugate vaccine.
    Vaccine. 2025;53:127080.
    PubMed         Abstract available
    
    
37. CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
    Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
    Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
    PubMed         Abstract available
    
    
38. LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
    Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
    Vaccine. 2025;54:127104.
    PubMed         Abstract available
    
    
39. WANG F, Zheng J, Qiu F, Yang Y, et al
    Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
    Vaccine. 2025;54:127128.
    PubMed         Abstract available
    
    
40. YE Q, Li H, Xie Z, Gao X, et al
    Corrigendum to "Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT)" [Vaccine 49 (7) (2025) 126815].
    Vaccine. 2025;54:127125.
    PubMed        
    
    
41. ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
    Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
    Vaccine. 2025;54:127117.
    PubMed         Abstract available
    
    
42. WEETS CM, Wilson R, Swadley H, Katz R, et al
    Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
    Vaccine. 2025;54:127121.
    PubMed         Abstract available
    
    

    
    Virology

43. BEAUDOIN-BUSSIERES G, Tauzin A, Dionne K, El Ferri O, et al
    Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1.
    Virology. 2025;607:110512.
    PubMed         Abstract available
    
    

    
    Virus Res

44. MATHUR G, Mahilkar S, Sunil S
    Generation and characterization of infectious clones of chikungunya virus from an Indian strain as a resource towards chikungunya vaccine research.
    Virus Res. 2025;356:199571.
    PubMed         Abstract available
    
    
45. MYERS ML, Conlon MT, Gallagher JR, Woolfork DD, et al
    Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.
    Virus Res. 2025 Mar 24:199563. doi: 10.1016/j.virusres.2025.199563.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.